S&P 500 darts to fresh all time highs as risk sentiment recovers


  • S&P 500 prints fresh highs as market sentiment to imminent tapering is dialled down. 
  • The FDA has approved the COVID-19 vaccine developed by Pfizer Inc PFEand BioNTech.

US stocks are flying high once again as risk sentiment improves in a dovetail fashion. Both FDA vaccine approvals as well as dialled down expectations of a Federal Reserve taper announcement have lifted spirits on Wall Street.

At the time of writing, the Dow Jones Industrial Average has climbed 0.7% to 35,380.85, with the S&P 500 up 0.27% and Nasdaq higher by 1.57%. Energy, communication services, and financials have been leading gainers while the utilities sector has been the steepest decliner.

Things kicked off on the bid following Friday's reaction to Dallas Federal Reserve President Robert Kaplan's comments.

Kaplan who has been among the US central bank's most forceful supporters for starting to reduce support for the economy said on Friday that he may need to adjust that view if the Delta variant of the coronavirus slows economic growth materially.

His comets have helped the market to second guess this Friday's highly anticipated Jackson Hole whereby the Fed's chairman, Jerome `Powell, is speaking. 

Powell has been expected to make an announcement over the timings of a tapering of the central bank's asset purchases. 

The event evokes the "Taper Tantrum" of 2013, when interest rates spiked higher and share prices tanked in reaction to then-Fed chair Ben Bernanke discussing its bond-buying program.

However, investors are less concerned about this week's event whereas Wall Street had otherwise been on high alert to the prospects of tighter money conditions and an announcement there of sooner than later. 

Meanwhile, the markets have also been given a shot in the arm as investors digest the announcements of full FDA approval of a COVID-19 vaccine.

The US Food and Drug Administration (FDA) granted full approval to the COVID-19 vaccine developed by Pfizer Inc PFEand BioNTech SE BNTX in a move that could accelerate inoculations in the United States.

This will be expected to raise the number of vaccinations as per population given that it will help to remove scepticism over the vaccination which opens the door to more mandates. 

Pfizer and U.S.-listed shares of BioNTech were up 2.7% and 8.3%, respectively.

Rival Moderna Inc MRNA gained 5.9%.

S&P 500 technical analysis

Following the strong bullish candle formation printed last week, as eclipsed in the chart above, the market has gone on to rally to fresh highs.

More of the same can be expected for the days ahead so long as the old highs hold as support. 

Share: Feed news

Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.

If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.

FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.

The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.

Recommended content


Recommended content

Editors’ Picks

GBP/USD extends recovery gains to near 1.3250, as BoE looms

GBP/USD extends recovery gains to near 1.3250, as BoE looms

GBP/USD extends the recovery to near 1.3200 in European trading on Thursday, having found buyers near 1.3150. A fresh US Dollar pullback and a rebound in risk sentiment offer support to the pair ahead of the BoE policy announcements. 

GBP/USD News
EUR/USD advances to 1.1150, focus shifts to ECB-speak

EUR/USD advances to 1.1150, focus shifts to ECB-speak

EUR/USD is well-bid near 1.1150 in the European session on Thursday. The pair is underpinned by the renewed US Dollar retreat and an upbeat mood. Traders digest the Fed's dovish outlook, bracing for ECB-speak for fresh trading incentives. US data are also eyed. 

EUR/USD News
Gold price jumps back closer to all-time peak, $2,600 remains in sight amid fresh USD weakness

Gold price jumps back closer to all-time peak, $2,600 remains in sight amid fresh USD weakness

Gold price regains positive traction following the previous day's pullback from the all-time peak and builds on its steady intraday ascent heading into the European session on Thursday. 

Gold News
BoE expected to keep interest rate unchanged at 5% as price pressures persist

BoE expected to keep interest rate unchanged at 5% as price pressures persist

After a close call in August, the Bank of England’s September interest rate decision is keenly awaited for fresh cues on the bank’s future policy action and the pace of its bond sales.

Read more
Bitcoin surges to $62,000 mark after 50 bps Fed rate cut

Bitcoin surges to $62,000 mark after 50 bps Fed rate cut

Bitcoin and Ripple eye for a rally as they break and find support around their resistance barrier. Meanwhile, Ethereum demonstrates signs of recovery as it approaches a critical resistance level, indicating that an upward rally could be on the horizon if it successfully breaks through.

Read more
Moneta Markets review 2024: All you need to know

Moneta Markets review 2024: All you need to know

VERIFIED In this review, the FXStreet team provides an independent and thorough analysis based on direct testing and real experiences with Moneta Markets – an excellent broker for novice to intermediate forex traders who want to broaden their knowledge base.

Read More

Forex MAJORS

Cryptocurrencies

Signatures